Related Experiment Video

Updated: Jan 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K

Correction: Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute

Hayden L Bell1, Helen J Blair1, Mankaran Singh1

  • 1Wolfson Childhood Cancer Research Centre, Translation and Clinical Research Institute Newcastle University Centre for Cancer , Newcastle Upon Tyne, UK.

Cancer Cell International
|November 7, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K

Related Experiment Videos

Last Updated: Jan 12, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.5K
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.6K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

Articles linked to this work by shared authors, journal, and citation graph.

Somatic Mitochondrial-Nuclear DNA Transfer in Lymphoproliferative Disorders.

EJHaem·2026

EARLY RESPONSE AND GENETICS DEFINE RELAPSE RISK AFTER FRONTLINE BLINATUMOMAB IN CHILDHOOD B-ALL: A COHORT STUDY.

Blood advances·2026

Reframing leukemia-niche interactions: the emerging role of the marrow adipocyte lineage.

Haematologica·2026

Combining inotuzumab ozogamicin with the p38 inhibitor BIRB 796 and venetoclax exerts synergistic cytotoxicity in B-cell precursor acute lymphoblastic leukemia including very high risk t(17;19) acute lymphoblastic leukemia.

Haematologica·2026

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A Phase I Dose-Escalation Study of Navitoclax, Venetoclax, and Decitabine.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

First-year results of the International Leukemia/Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.

Haematologica·2026

Targeting the Notch signaling pathway in digestive system cancers: from bench to bedside.

Cancer cell international·2026

Enhanced survival through repeated photodynamic therapy and almost complete tumor regression by prior radiation therapy in an orthotopic rat bladder cancer model.

Cancer cell international·2026

Characteristics of fusion genes in breast cancer.

Cancer cell international·2026

Cold atmospheric plasma affects metabolic processes in malignant melanoma.

Cancer cell international·2026

NPTXR as a novel therapeutic target: efficacy of antibody-drug conjugates in preclinical tumor models.

Cancer cell international·2026

Quantifying target antigen-dependent CAR T-cell performance against AML.

Cancer cell international·2026

A scalable outpatient framework for BI-RADS 2-4B breast nodule management: an iodine-DMSO transdermal protocol.

Frontiers in health services·2026

Spontaneous rupture of the urinary bladder and hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a case report.

Journal of surgical case reports·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us